Inositol and hormonal balance: a modern approach to fertility and PCOS

Inositol research
Author Avatar
Inositol research

Introduction: when a cycle is not just about menstruation

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age.

It can manifest as acne, menstrual irregularities, excessive hair growth (hirsutism), weight problems and infertility.

Modern nutraceuticals are increasingly focusing on the role of inositol as one of the key tools for maintaining hormone balance.

At Vitafoods Europe 2025, inositol was mentioned in connection with new clinical approaches to fertility, metabolic syndrome and even emotional well-being. But how exactly it works – let’s explore further.

A woman holding a package of Inositol

What is inositol?

Inositol is a pseudovitamin that is structurally similar to glucose. There are several isomers of inositol, of which the best known are myo-inositol and D-chiro-inositol.

Both are naturally present in the cells of the human body and have important roles in insulin signaling as well as ovarian function.

🟢 Myo-inositol supports insulin sensitivity and egg quality.
🟠 D-chiro-inositol has more of an effect on androgen synthesis.

The key is the balance between the two, the most commonly used ratio is 40:1 (myo to D-chiro).

Inositol in CKD: mechanisms of action

The main mechanisms through which inositol affects the symptoms of SPCN:

  • Improving insulin sensitivity ✅ Improving insulin sensitivity ✅ Improving insulin sensitivity

  • Reduction of androgen levels ✅ Reduction of androgen levels

  • Restoration of the ovulatory cycle ✅ Restoration of the ovulatory cycle

  • Improvement of oocyte quality ✅ Improvement of oocyte quality ✅ Improvement of oocyte quality

  • Improvement of psycho-emotional state ✅ Improvement of psycho-emotional state ✅ Improvement of psycho-emotional state

Table 1: Effects of inositol in PCOS

Effect Research / Source
Decreased testosterone Gerli et al., Eur Rev Med Pharmacol Sci, 2007
Improved ovulation Nestler et al., Fertil Steril, 2008
Insulin regulation Genazzani et al., Gynecol Endocrinol, 2008
Increased fertility Raffone et al., Gynecol Endocrinol, 2010

The evidence base: what does the research say?

In numerous clinical studies, inositol has demonstrated efficacy in:

  • reducing insulin resistance (especially in overweight women),

  • reduction of hirsutism and acne,

  • increasing the chances of pregnancy in women with CKD.

For example, a review by Facchinetti et al, Int J Endocrinol, 2016 indicates that regular supplementation with myo-inositol (2-4 g/day) for 3-6 months significantly improves fertility.

Inositol and fertility: not just for PCOS

Inositol may also be useful in cases of unexplained infertility, in preparation for IVF (in vitro fertilization) and to improve egg quality in women after age 35.

Table 2. Role of inositol in fertility (without PCOS)

Situation Effect of inositol Source
ECHO Improving oocyte quality Papaleo et al., Gynecol Endocrinol, 2009
Infertility of unknown etiology Restoring ovulation, reducing stress Regidor et al., Reprod Biol Endocrinol, 2018
Women after 35 Improving ovarian function Chiu et al., Reprod Sci, 2020

New delivery systems for inositol (Vitafoods 2025)

At Vitafoods Europe 2025, manufacturers presented innovative forms of inositol delivery:

  • chewable tablets with a pleasant flavor (targeting young women);

  • liposomal formulas with B vitamins for improved absorption;

  • combinations of inositol with NAC, folic acid and melatonin to improve sleep and metabolism.

These approaches open the way to more personalized support strategies for women with SPCN and beyond.

Conclusions and recommendations

  • Inositol is a safe and effective nutraceutical strategy for SPCN.

  • The optimal ratio of myo- to D-chiro-inositol (40:1) demonstrates the best clinical results.

  • Inositol has the potential to support female fertility even in the absence of a diagnosis of PCOS.

  • It is important to choose formulas with an evidence base and a convenient dosage form.

List of references

  1. Gerli S, et al. Eur Rev Med Pharmacol Sci. 2007.

  2. Nestler JE, et al. Fertil Steril. 2008.

  3. Genazzani AD, et al. Gynecol Endocrinol. 2008.

  4. Facchinetti F, et al. Int J Endocrinol. 2016.

  5. Papaleo E, et al. Gynecol Endocrinol. 2009.

  6. Raffone E, et al. Gynecol Endocrinol. 2010.

  7. Regidor PA, et al. Reprod Biol Endocrinol. 2018.

  8. Chiu TT, et al. Reprod Sci. 2020.

About the Author

Author Photo

Kateryna Braitenko is a Ukrainian journalist and author specializing in writing articles for pharmaceutical publications. She holds a philology degree from Donetsk National University and a pharmaceutical degree from the National Pharmaceutical University in Kharkiv. She lives in Kyiv and continues her career, covering relevant issues in medicine and pharmaceuticals.





0.0
0.0 out of 5 stars (based on 0 reviews)
Excellent0%
Very good0%
Average0%
Poor0%
Terrible0%
Scroll to Top